Combining Three Different Pretransplantation Scores Improves Predictive Value in Patients after Haploidentical Stem Cell Transplantation with Thiotepa, Busulfan, and Fludarabine Conditioning and Post-Transplantation Cyclophosphamide.


Journal

Transplantation and cellular therapy
ISSN: 2666-6367
Titre abrégé: Transplant Cell Ther
Pays: United States
ID NLM: 101774629

Informations de publication

Date de publication:
07 2021
Historique:
received: 09 12 2020
revised: 19 02 2021
accepted: 10 03 2021
pubmed: 30 3 2021
medline: 16 7 2021
entrez: 29 3 2021
Statut: ppublish

Résumé

One hundred and sixty-one patients underwent haploidentical stem cell transplantation (haploSCT) with thiotepa, busulfan, and fludarabine conditioning followed by post-transplantation cyclophosphamide (PTCy) (on days +3 and +4) and tacrolimus as graft-versus-host disease prophylaxis. Forty-two percent of patients had a high or very high revised Disease Risk Index (rDRI), 55% had an European Society for Blood and Marrow Transplantation risk score (EBMT-RS) ≥4, and 36% had an age-adjusted Hematopoietic Cell Transplant Comorbidity Index (HCT-CI-age) score ≥3. Each of these was considered an unfavorable score. Using the pretransplantation unfavorable scores that had an independent impact on each transplantation outcome studied in multivariate analysis allowed for better stratification of patient outcomes. Thus, the 3-year overall survival (OS) in patients with 0, 1, 2, and 3 unfavorable scores was 86%, 56%, 36%, and 24%, respectively. Nonrelapse mortality (NRM) was negatively impacted by the EBMT-RS and the HCT-CI-age score (3-year NRM in patients with 0, 1, and 2 unfavorable scores was 12%, 33%, and 43%, respectively), whereas the EBMT-RS and the rDRI had an impact on the 3-year relapse incidence (8%, 18%, and 41% in patients with 0, 1, and 2 unfavorable scores, respectively). In conclusion, our study shows that combining 2 or 3 of these well-defined pretransplantation scores improves the ability to predict transplantation outcomes in the setting of haploSCT with PTCy.

Identifiants

pubmed: 33775908
pii: S2666-6367(21)00769-7
doi: 10.1016/j.jtct.2021.03.021
pii:
doi:

Substances chimiques

Cyclophosphamide 8N3DW7272P
Thiotepa 905Z5W3GKH
Vidarabine FA2DM6879K
Busulfan G1LN9045DK
fludarabine P2K93U8740

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

614.e1-614.e8

Informations de copyright

Copyright © 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Auteurs

Albert Esquirol (A)

Hematology Department, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau and Jose Carreras Leukemia Research Institute, Universitat Autonoma of Barcelona, Barcelona, Spain. Electronic address: aesquirol@santpau.cat.

Maria Jesus Pascual (MJ)

Hematology Department, Hospital Regional Universitario, Malaga, Spain.

Irene Garcia-Cadenas (I)

Hematology Department, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau and Jose Carreras Leukemia Research Institute, Universitat Autonoma of Barcelona, Barcelona, Spain.

Beatriz Herruzo (B)

Hematology Department, Hospital Regional Universitario, Malaga, Spain.

Christelle Ferrà (C)

Hematology Department, Institut Català d'Oncologia Hospital Germans Trias i Pujol, Badalona, Spain and Universitat de Vic-Universitat Central de Catalunya, Catalonia, Spain.

Ariadna Pérez (A)

Hematology Department, Hospital Clinico Universitario, Valencia, Spain.

Alberto Torio (A)

Immunology Department, Hospital Regional Universitario, Malaga, Spain.

Anna Torrent (A)

Hematology Department, Institut Català d'Oncologia Hospital Germans Trias i Pujol, Badalona, Spain and Universitat de Vic-Universitat Central de Catalunya, Catalonia, Spain.

Marian Cuesta (M)

Hematology Department, Hospital Regional Universitario, Malaga, Spain.

Rodrigo Martino (R)

Hematology Department, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau and Jose Carreras Leukemia Research Institute, Universitat Autonoma of Barcelona, Barcelona, Spain.

Jorge Sierra (J)

Hematology Department, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau and Jose Carreras Leukemia Research Institute, Universitat Autonoma of Barcelona, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH